Endometriosis: 176 Million Women And No Cure In Sight
Executive Summary
With a gap in endometriosis treatments on the market, Citeline analyst Benjamin Graham looks at the pipeline to see what those suffering can expect in the coming years.
You may also be interested in...
Still room for innovators in women's health, says Bayer
Women's health – a hot area at the moment for many generic companies – is one of Bayer Healthcare's key therapy areas of focus; and there is plenty of room for more innovation-based R&D in this space, according to UK & Ireland chief Dr Alexander Moscho.
Bayer teams with Evotec on endometriosis
Bayer and Evotec have signed a five-year collaboration to develop clinical candidates for endometriosis, a condition that Datamonitor Healthcare analysts view as offering the most attractive market for pharma companies in the women's health space.
Tuberculosis: An Old Killer Proving Difficult To Best
With the announcement that tuberculosis surpassed HIV/AIDS in attributable deaths from infectious diseases worldwide, there has been a renewed interest in the development of new treatments and regimens for dealing with what is now the world’s number one infectious disease killer.